Safety of voriconazole and dose individualization

被引：59

作者：

Lutsar, I ^{[1
]}

Hodges, MR ^{[1
]}

Tomaszewski, K ^{[1
]}

Troke, PF ^{[1
]}

Wood, ND ^{[1
]}

机构：

[1] Pfizer Ltd, Global Res & Dev, Sandwich CT13 9NJ, Kent, England

来源：

CLINICAL INFECTIOUS DISEASES | 2003年 / 36卷 / 08期

关键词：

D O I：

10.1086/374248

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1087 / 1088

页数：2

共 6 条

[1] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients [J].

Ally, R ;

Schürmann, D ;

Kreisel, W ;

Carosi, G ;

Aguirrebengoa, K ;

Dupont, B ;

Hodges, M ;

Troke, P ;

Romero, AJ .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) :1447-1454

[2] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[3] The safety of voriconazole [J].

Potoski, BA ;

Brown, J .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (10) :1273-1275

[4]

TAN KKC, 2001, 41 INT C ANT AG CHEM

[5]

*US FDA, 2001, BRIEF DOC VOR OR INT

[6] Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. [J].

Walsh, TJ ;

Pappas, P ;

Winston, DJ ;

Lazarus, HM ;

Petersen, F ;

Raffalli, J ;

Yanovich, S ;

Stiff, P ;

Greenberg, R ;

Donowitz, G ;

Lee, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :225-234

← 1 →